Gilead Sciences

GILDApproved

Founded in 1987, Gilead Sciences has established itself as a premier biopharmaceutical company with a strong track record of bringing transformative medicines to market. The company generates substantial revenue from its portfolio of approved drugs, particularly in HIV and hepatitis, while investing heavily in R&D to advance next-generation therapies in oncology, inflammation, and infectious diseases. With a market capitalization of over $170 billion and a diversified pipeline, Gilead continues to be a major player in the global pharmaceutical landscape.

Market Cap

$170.3B

Employees

14,000-16,000

Focus

Biotech

GILD · Stock Price

USD 137.21+78.30 (+132.91%)

Historical price data

AI Company Overview

Technology Platform

Gilead specializes in antiviral drug discovery with expertise in nucleoside/nucleotide analogs, prodrug chemistry, and cell therapy platforms including CAR-T technologies acquired through Kite Pharma.

Pipeline Snapshot

993

993 drugs in pipeline, 257 in Phase 3

Drug	Indication	Stage
Regimen：BIC+FTC+TAF	HIV Infection	Approved
BIKTARVY 50Mg-200Mg-25Mg Tablet	Human Immunodeficiency Virus	Approved
Truvada + Current HAART regimen	HIV Infections	Approved
Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg	HIV Infections	Approved
Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch	HIV-1-infection	Approved

Funding History

Total raised: $86.3M

IPO$86.3MUndisclosedJan 22, 1992

FDA Approved Drugs

TRODELVYBLAApr 22, 2020

Opportunities

Gilead has significant growth opportunities through its expanding oncology portfolio, particularly CAR-T therapies, and potential breakthrough treatments in HIV prevention and cure research.

The company's strong cash position enables strategic acquisitions and partnerships to enhance its pipeline diversity.

Risk Factors

Key risks include patent cliff exposure for major HIV and hepatitis products, intense competition in oncology markets, and regulatory challenges for new indications.

Clinical trial failures in key programs like NASH could impact growth prospects.

Competitive Landscape

Gilead competes with major pharmaceutical companies including ViiV Healthcare in HIV, Bristol Myers Squibb and Novartis in CAR-T therapies, and numerous players in hepatitis and infectious diseases. The company differentiates through its deep antiviral expertise and proven track record of bringing breakthrough therapies to market.

Publications

Patents

Pipeline

993

FDA Approvals